Chronic Myelogenous Leukemia

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

What is Chronic Myelogenous Leukemia (CML)?

Leukaemia is cancer of the white blood cells. There are essentially two broad categories of leukemia – acute and chronic.

Chronic Myelogenous Leukemia Symptoms

Chronic Myelogenous Leukemia Diagnosis

Chronic Myelogenous Leukemia Treatment

Chronic Myelogenous Leukemia Management

Chronic Myelogenous Leukemia Risk Factors

Chronic Myelogenous Leukemia Prognosis

Chronic Myelogenous Leukemia Pathogenesis

Chronic Myelogenous Leukemia Epidemiology

Chronic Myelogenous Leukemia Research

Chronic Myelogenous Leukemia Classification

Latest Chronic Myelogenous Leukemia News and Research

Purdue researcher receives $1.38 million to fight against drug-resistant malaria in developing countries

A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries.

15 Sep 2023

For uninsured people with cancer, securing care can be like spinning a roulette wheel

Eighteen months after April Adcox learned she had skin cancer, she finally returned to Charleston's Medical University of South Carolina last May to seek treatment.

10 Apr 2023

Researchers set sights on a new therapeutic target for aggressive breast cancer

Researchers at VCU Massey Cancer Center have set their sights on a new therapeutic target for an aggressive form of breast cancer with limited treatment options.

25 Oct 2022

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Researchers investigated the efficacy of two multi-kinase inhibitors, olverembatinib and ponatinib, in inhibiting SARS-CoV-2 omicron-mediated cytokine release in human peripheral blood mononuclear cells.

10 Feb 2022

Study provides a new target for therapeutic intervention in Parkinson's disease

In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.

14 Nov 2021

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021

Previously approved drugs starting points for COVID-19 therapeutics

Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).

11 Apr 2021

Weedy grass may be effective against several human diseases

Native to the southeastern United States, a weedy grass has spread northward to Canada and also made its way to Australia and Japan. Andropogon virginicus grows densely packed and up to seven feet tall, disrupting growth patterns of other plants and competing for resources.

8 Mar 2021

Researchers identify new path to defeating chronic myelogenous leukemia

Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.

18 Sep 2020

Potential inhibitors of SARS-CoV-2 identified

Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.

16 Aug 2020

UCLA researchers discover new way to eliminate leukemia stem cells

The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.

15 Oct 2019

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival.

22 Mar 2019

Novel approach induces cell death via dual targeting of DNA repair mechanism

Proteins commonly known as BRCA - short for BReast CAncer susceptibility gene- serve a critical role in cellular DNA repair, but when mutated they allow genetic errors to replicate, facilitating cancer development.

13 Jun 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.

6 Feb 2017

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.

10 Jan 2017

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.

4 Oct 2016

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease.

30 Sep 2016